secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kronos Bio, Inc. (—)
CIK:        0001741830
Form:       8-K
Filed at:   2025-06-20T23:59:59+00:00
Accession:  0001213900-25-055915
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kronos Bio acquired by Concentra Biosciences for $0.57/share plus CVR; delisting effective
--------------------------------------------------------------------------------

- Tender offer closed June 18 with 44.5M shares (72.9% outstanding) tendered; merger completed June 20.
- Shareholders receive $0.57 cash per share plus one non-transferable contingent value right (CVR) per share.
- All conditions to tender offer and merger satisfied; shares to be delisted from Nasdaq and deregistered.
- Board of directors resigned; new directors and officers from Concentra Merger Sub appointed (CEO Kevin Tang).
- Company became wholly owned subsidiary of Concentra Biosciences; articles and bylaws amended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/0001213900-25-055915-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1741830/000121390025055915/ea0246047-8k_kronos.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-055915

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer